Clinical Trials Directory

Trials / Completed

CompletedNCT01686087

Attaining and Maintaining Wellness in Obsessive-compulsive Disorder

Attaining and Maintaining Wellness in OCD

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
137 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The goal of this study is to understand whether patients with obsessive-compulsive disorder (OCD) on serotonin reuptake inhibitors (SRIs) who receive a type of Cognitive-behavioral therapy called Exposure and Ritual Prevention (EX/RP) can discontinue their medication if they first do well with EX/RP.

Detailed description

This study begins with a Preparatory Phase, wherein all eligible participants receive up to 25 sessions of Exposure and Ritual Prevention (EX/RP) therapy. At the end of the Preparatory Phase, those who have achieved wellness (mild to minimal symptoms) enter the Study Phase. Those who do not achieve wellness will not continue in the study and are referred for treatment elsewhere. Those who enter the Study Phase are then assigned by chance to one of two groups. One group will continue on the SRI medication and the other group will discontinue the SRI gradually over 4-6 weeks as it is replaced with a placebo (sugar pill). Neither patients nor study staff will know which group a participant is in. Both groups will continue to receive monthly sessions of EX/RP. The study will examine who has the best response to treatment in this study, including taking blood samples for genetic testing to see whether there are genes that can predict who will or will not benefit from EX/RP.

Conditions

Interventions

TypeNameDescription
BEHAVIORALMonthly Booster Sessions of EX/RP45 minute EXRP booster sessions each month
PROCEDUREVisits with MD and independent evaluatorsAll patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.

Timeline

Start date
2012-10-01
Primary completion
2018-06-01
Completion
2018-07-01
First posted
2012-09-17
Last updated
2019-03-13

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01686087. Inclusion in this directory is not an endorsement.